export interface KeyCapability {
  title: string;
  technical: string;
  scientific: string;
  business: string;
  genomicUseCasesParagraph?: string;
}

export interface ValuePropositionSection {
  audience: string;
  points: string[];
}

export interface GenomicUseCaseGridItem {
  label: string;
  iconName: string;
  color: string;
}

export interface CoPilotDetailContent {
  slug: string;
  pageTitle: string; 
  heroSubtitle?: string; 
  vision: string;
  genomicInsightsOverview?: string;
  coreProblemIntro?: string;
  coreProblemPoints?: string[];
  buildsOnStackIntro?: string;
  buildsOnStackPoints?: string[];
  genomicUseCasesGrid?: GenomicUseCaseGridItem[];
  keyCapabilities: KeyCapability[];
  valuePropositionIntro?: string;
  valuePropositionSections: ValuePropositionSection[];
  conclusion: string;
}

// Populate this with the actual content for each co-pilot
// Using PrecisionRad as the primary example based on the provided markdown
export const coPilotDetailsData: Record<string, CoPilotDetailContent> = {
  "precision-rad": {
    slug: "precision-rad",
    pageTitle: "PrecisionRad Co-Pilot: AI Genomics Meets Advanced Radiotherapy for Transformative Cancer Care",
    heroSubtitle: "Revolutionizing radiation oncology by integrating AI-driven genomic insights for truly personalized and predictive targeted radiation therapy.",
    vision: "The PrecisionRad Co-Pilot aims to revolutionize targeted radiation therapy by empowering clinicians and researchers with an AI-driven platform that integrates multi-modal data, advanced analytics, and intelligent decision support. Our vision is to enhance treatment precision, personalize care based on individual tumor biology and patient genetics, optimize workflows, and ultimately improve patient outcomes while minimizing toxicities.",
    genomicInsightsOverview: "PrecisionRad's integrated AI-powered `analyze_single_variant` capability is fundamental to personalizing radiation therapy. It facilitates: \n1. Prediction of tumor radiosensitivity or resistance based on functional impacts of somatic mutations in DNA repair/cell cycle genes. \n2. Forecasting of normal tissue radiotoxicity by analyzing germline variants influencing radiation susceptibility. \n3. Enablement of biologically guided dose painting by identifying radioresistant tumor sub-regions via their mutational profiles. \n4. Rapid interpretation of VUS in hereditary cancer genes for holistic patient context in radiotherapy and genetic counseling. \n5. Guidance on concurrent/adjuvant systemic therapies by assessing how tumor mutations affect sensitivity to those agents. \n6. Improved patient stratification for clinical trials and discovery of novel radio-genomic biomarkers. \nThis tailors radiation plans by understanding individual tumor/patient genomics to maximize efficacy and minimize side effects.",
    coreProblemIntro: "Targeted radiation therapy, a cornerstone of modern cancer treatment, grapples with inherent complexities that PrecisionRad Co-Pilot seeks to address:",
    coreProblemPoints: [
      "Complex Treatment Planning: Accurately defining tumor volumes and organs at risk (OARs), and optimizing radiation delivery, remains intricate and resource-intensive.",
      "Biological Variability & Radio-Resistance/Sensitivity: Tumors and patients exhibit diverse responses to radiation due to genetic makeup (both tumor and germline), tumor microenvironment factors, and intrinsic DNA repair capabilities. Tailoring treatment to this deep biological variability is a major hurdle.",
      "Dynamic Changes During Treatment (Adaptive Radiotherapy - ART): Patient anatomy and tumor biology can change significantly over a multi-week treatment course, potentially compromising the original plan's accuracy and efficacy.",
      "Risk of Normal Tissue Toxicity: Predicting, mitigating, and managing radiation-induced side effects in healthy tissues based on individual susceptibility is critical for patient quality of life.",
      "Data Silos & Integration Challenges: Radiation oncology relies on a wealth of data—imaging (CT, MRI, PET), dosimetry, patient-reported outcomes, and increasingly, molecular/genomic information. Integrating these disparate sources for holistic, intelligent decision-making remains challenging."
    ],
    buildsOnStackIntro: "The PrecisionRad Co-Pilot's technology foundation is deeply rooted in its capability to integrate and interpret complex genomic data, enabling the following key use cases powered by its integrated Evo2-style `analyze_single_variant` capability (providing functional impact predictions, confidence scores, and delta_scores for mutations):",
    buildsOnStackPoints: [
        "**Predicting Tumor Radiosensitivity/Radioresistance:** PrecisionRad leverages the AI to analyze somatic (tumor) mutations in key DNA repair (e.g., TP53, ATM) and cell cycle genes. By understanding the functional impact of these mutations (e.g., a high-impact pathogenic TP53 R175H identified by the AI), it predicts if a tumor is likely to be more sensitive or resistant to radiation, guiding considerations for dose adaptation or combination therapies.",
        "**Forecasting Normal Tissue Radiotoxicity:** PrecisionRad analyzes a patient's inherited (germline) genetic variations using the AI. This identifies variants in genes affecting processes like oxidative stress or inflammation that might predispose a patient to higher-than-average normal tissue side effects, allowing for proactive planning adjustments.",
        "**Enabling Biologically Guided Dose Painting:** For heterogeneous tumors, PrecisionRad uses the AI to assess spatially resolved genomic data (e.g., from multiple biopsies). If a sub-region is found to be particularly radioresistant due to its unique mutational profile (as interpreted by the AI), this guides higher, targeted radiation doses (dose painting) precisely to that area.",
        "**Rapid VUS Interpretation for Holistic Patient Context:** If patients undergoing radiotherapy also have hereditary cancer syndromes or Variants of Uncertain Significance (VUS) in predisposition genes (e.g., BRCA1), PrecisionRad's AI rapidly assesses these VUS. This turns genetic uncertainty into actionable clarity, providing crucial context for overall treatment strategy and genetic counseling.",
        "**Guiding Concurrent or Adjuvant Systemic Therapies:** The AI's ability to predict the functional impact of tumor mutations helps PrecisionRad inform whether the tumor might also be sensitive or resistant to concurrent/adjuvant systemic agents (chemotherapy, targeted drugs), enabling a more synergistic combination strategy alongside radiotherapy.",
        "**Smarter Patient Stratification & Biomarker Discovery:** For advancing radio-oncology, PrecisionRad utilizes AI-derived genomic features (like variant impact scores from many patients) to identify ideal candidates for clinical trials of novel radiation techniques or drug-radio combinations. This also aids in discovering new radio-genomic biomarkers – genetic signatures that predict radiation response or toxicity."
    ],
    genomicUseCasesGrid: [
      { label: "Predicting Tumor Radiosensitivity/Radioresistance", iconName: "Activity", color: "text-blue-400" },
      { label: "Forecasting Normal Tissue Radiotoxicity", iconName: "Shield", color: "text-red-400" },
      { label: "Enabling Biologically Guided Dose Painting", iconName: "Layers", color: "text-green-400" },
      { label: "Rapid VUS Interpretation", iconName: "Lightbulb", color: "text-yellow-400" },
      { label: "Guiding Concurrent or Adjuvant Systemic Therapies", iconName: "Beaker", color: "text-purple-400" },
      { label: "Smarter Patient Stratification & Biomarker Discovery", iconName: "Users", color: "text-orange-400" }
    ],
    keyCapabilities: [
      {
    title: "AI-Enhanced Treatment Planning & Quality Assurance",
    technical: "PrecisionRad leverages deep learning AI to accelerate and refine treatment blueprints. This includes AI-assisted contouring of tumors and organs at risk (OARs) on CT/MRI scans, intelligent algorithms that propose optimal radiation beam arrangements and fluence maps, and predictive dosimetry models. Automated systems flag plans for quality assurance, ensuring adherence to best practices, while genomic insights directly inform the definition of biological target volumes, especially for radioresistant sub-regions.",
    scientific: "This AI integration drives more consistent and highly accurate target delineation, reducing inter-observer variability. It opens avenues for exploring novel, biologically-informed planning strategies where, for instance, radioresistant tumor regions identified via genomics are specifically targeted. This capability is foundational for developing sophisticated, biologically adaptive radiotherapy approaches.",
    business: "Clinics see increased efficiency in the complex treatment planning process, leading to improved plan quality and potentially better patient outcomes. It promotes standardization of best practices across the institution and establishes a clear pathway towards implementing advanced, biologically adaptive and personalized radiotherapy, enhancing the clinic's reputation as an innovative leader.",
    genomicUseCasesParagraph: "PrecisionRad utilizes its `analyze_single_variant` AI capability to directly enhance treatment planning and QA by: \n1. **Informing target definition**: If specific tumor sub-regions are identified (e.g., through multi-sample analysis or imaging-genomic correlation) to harbor mutations predicted by the AI to confer high radioresistance (e.g., specific TP53 gain-of-function variants with strong pathogenic scores), these regions can be delineated as biological targets for dose escalation (dose painting). \n2. **Guiding selection of OAR constraints**: Germline variants analyzed by `analyze_single_variant` that indicate heightened sensitivity of certain normal tissues to radiation can inform more conservative dose constraints for those specific OARs during planning. \n3. **Contributing to QA by providing biological rationale**: When AI-driven plans incorporate dose escalation to genomically-defined resistant areas, the underlying `analyze_single_variant` predictions (pathogenicity, delta_score) provide a verifiable biological basis for these advanced planning decisions, enhancing the QA process."
  },
  {
    title: "Radio-Genomics & Biomarker Integration for Personalization",
    technical: "Our platform seamlessly integrates multi-modal patient data. This includes genomic information (germline/somatic variants analyzed via an Evo2-style `analyze_single_variant` API for functional impact scores), transcriptomics, and proteomics, alongside quantitative features extracted from CT, PET, and MRI scans via advanced radiomics pipelines. Sophisticated AI models then correlate these comprehensive molecular and imaging biomarkers with radiation response and toxicity profiles.",
    scientific: "This holistic approach provides a much deeper understanding of the biological underpinnings of tumor radiosensitivity and resistance, as well as individual predispositions to normal tissue toxicity. It enables non-invasive tumor characterization through radiomics and helps identify which patients are most likely to benefit from personalized strategies like dose escalation/de-escalation, specific radiosensitizers, or alternative therapeutic combinations based on their unique genomic and imaging profile.",
    business: "PrecisionRad empowers clinics to effectively stratify patients for clinical trials, accelerating research and development of novel predictive biomarkers (a source of potential IP). This cutting-edge approach attracts patients seeking highly personalized treatments and strongly supports value-based care initiatives by optimizing treatment selection and resource allocation for maximum patient benefit.",
    genomicUseCasesParagraph: "PrecisionRad's integrated AI-powered `analyze_single_variant` capability is fundamental to personalizing radiation therapy. It facilitates: \n1. **Prediction of tumor radiosensitivity or resistance** based on functional impacts of somatic mutations in DNA repair/cell cycle genes. \n2. **Forecasting of normal tissue radiotoxicity** by analyzing germline variants influencing radiation susceptibility. \n3. **Enablement of biologically guided dose painting** by identifying radioresistant tumor sub-regions via their mutational profiles. \n4. **Rapid interpretation of VUS in hereditary cancer genes** for holistic patient context in radiotherapy and genetic counseling. \n5. **Guidance on concurrent/adjuvant systemic therapies** by assessing how tumor mutations affect sensitivity to those agents. \n6. **Improved patient stratification for clinical trials and discovery of novel radio-genomic biomarkers**. \nThis tailors radiation plans by understanding individual tumor/patient genomics to maximize efficacy and minimize side effects."
  },
  {
    title: "Intelligent Adaptive Radiotherapy (ART) Support", // Added this title as it was missing from your prompt but present in my previous response for PrecisionRad
    technical: "PrecisionRad's ART module employs AI for automated detection of anatomical and biological changes using daily/weekly on-board imaging (e.g., CBCT). It performs rapid simulations of the dosimetric impact of these changes on the current treatment plan. AI-driven algorithms then provide recommendations for replanning triggers, potentially further refined by genomic biomarkers that predict a tumor's propensity for rapid evolution or resistance development during therapy.",
    scientific: "This capability ensures more accurate and adaptive radiation dose delivery throughout the entire treatment course, responding dynamically to tumor shrinkage, swelling, or shifts in organs at risk. It enables robust research into optimal ART strategies, allowing for stratification of patients based on genomic predictors to identify who would benefit most from adaptation, thereby personalizing the adaptive approach itself.",
    business: "Implementing PrecisionRad's intelligent ART positions a clinic as a leader in advanced, responsive cancer care. This proactive management of treatment dynamics can lead to improved patient outcomes, reduce complications from inaccurate dosing, and enhance overall treatment efficacy, offering a distinct competitive advantage.",
    genomicUseCasesParagraph: "PrecisionRad's `analyze_single_variant` AI can inform ART strategies by: \n1. **Identifying tumors with genomic signatures** (e.g., mutations in genes associated with rapid clonal evolution or acquired resistance, as flagged by the AI) that may benefit most from frequent monitoring and adaptive replanning. \n2. **During adaptation**, if new imaging or biopsy data reveals emerging resistant subclones with specific mutations, the AI's functional impact assessment of these new variants can guide adjustments in the adapted plan. \n3. **Providing a biological basis for the *frequency* and *nature* of adaptations**, moving beyond purely geometric changes to incorporate predictive genomics into the ART decision loop."
  },
  {
    title: "Treatment Outcome & Toxicity Prediction",
    technical: "PrecisionRad develops advanced predictive models for Tumor Control Probability (TCP) and Normal Tissue Complication Probability (NTCP). These models uniquely incorporate not only clinical, dosimetric, and imaging data, but also crucially, detailed genomic risk factors derived from our `analyze_single_variant` AI's analysis (e.g., summed impact scores of relevant mutations). An LLM then facilitates the presentation of these personalized risk/benefit profiles in an accessible manner.",
    scientific: "This integrated approach leads to more accurate and personalized prognostication for patients. It allows for better-informed shared decision-making conversations by clearly outlining individualized predictions. Furthermore, it helps identify complex interacting factors, including specific genomic signatures and their AI-predicted functional consequences, that drive treatment success or failure, offering rich avenues for translational research.",
    business: "Clinics can significantly enhance patient counseling and manage expectations more effectively with these personalized predictions. The resulting data provides a robust foundation for quality improvement initiatives, internal benchmarking, and the development of targeted, personalized survivorship plans, ultimately improving patient satisfaction and demonstrating a commitment to cutting-edge, data-driven care.",
    genomicUseCasesParagraph: "The `analyze_single_variant` genomic engine is crucial for enhancing TCP/NTCP models within PrecisionRad by: \n1. For TCP, providing AI-derived functional impact scores (pathogenicity, delta_score) of somatic tumor mutations, quantifying their likely contribution to radioresistance (e.g., a pathogenic TP53 variant flagged by the AI) or sensitivity, directly refining outcome predictions. \n2. For NTCP, assessing germline variants analyzed by `analyze_single_variant` in pathways like DNA repair and inflammation to identify individual patient predispositions to specific radiation toxicities. \n3. These granular genomic risk factors, derived from `analyze_single_variant`'s outputs, allow for the creation of more accurate and personalized predictions of treatment success and potential side effects, improving shared decision-making."
  },
  {
    title: "Knowledge Integration & Research Support",
    technical: "The platform features an LLM for intuitive, natural language querying of extensive knowledge bases, including radiation oncology guidelines, the latest published research, and crucially, internal anonymized patient cohort data enriched with genomic findings from our `analyze_single_variant` AI. It also includes robust tools for structured data capture optimized for research, and intelligent clinical trial matching algorithms that leverage comprehensive patient profiles including detailed genomic markers.",
    scientific: "This capability actively facilitates evidence-based practice and fosters a culture of continuous learning within the clinical team. It streamlines the collection of high-quality, multi-modal data, essential for sophisticated clinical and translational research. By incorporating deep genomic insights from the AI into trial matching, it significantly improves accrual to highly relevant, genomically-informed clinical trials, advancing the science of personalized radiation oncology.",
    business: "PrecisionRad enhances a clinic's research profile and its contribution to advancing oncological knowledge. It supports robust continuous quality improvement cycles and drives innovation in patient care. This commitment to data-driven research and evidence-based practice can be a significant differentiator, attracting talent and research funding.",
    genomicUseCasesParagraph: "PrecisionRad's `analyze_single_variant` capability fuels knowledge integration and research by: \n1. **Generating standardized, AI-interpreted functional impact data (predictions, delta scores, confidence)** for every analyzed variant, creating rich, queryable genomic datasets essential for retrospective and prospective research. \n2. **Enabling researchers to investigate correlations between specific AI-predicted variant effects** (e.g., 'Likely Pathogenic' with high negative delta_score) and clinical outcomes, thereby accelerating the discovery and validation of novel radio-genomic biomarkers. \n3. **Facilitating more precise patient stratification for clinical trials** by incorporating the AI's assessment of variant pathogenicity and functional impact, moving beyond simple gene lists to actual predicted biological consequences for trial eligibility and arm assignment."
  }
    ],
    valuePropositionSections: [
        {
          audience: "Radiation Oncologists & Clinical Teams",
          points: [
            "**Elevate Treatment Precision:** Move beyond standard protocols with AI-driven plans that target the unique biological drivers of a patient's tumor.",
            "**Unlock True Personalization:** Craft treatment strategies based on individual tumor biology and germline predispositions to toxicity, not just population averages.",
            "**Streamline Clinical Workflow:** Leverage AI-assistance to accelerate contouring, plan evaluation, and adaptive re-planning decisions, freeing up time for patient care.",
            "**Proactively Manage Toxicity:** Anticipate and mitigate treatment-related side effects using predictive models based on individual genetic risk factors.",
            "**Stay at the Forefront of Oncology:** Seamlessly integrate the latest radio-genomic research and evidence into daily practice, with tools that support both clinical care and investigation."
          ]
        },
        {
          audience: "Medical Physicists & Dosimetrists",
          points: [
            "**Biologically-Informed Dosimetry:** Incorporate novel biological targets and constraints directly into the planning process, optimizing for radio-sensitivity and resistance.",
            "**Execute Advanced Plans with Confidence:** Gain AI-powered support to efficiently design, validate, and deliver complex, personalized treatment techniques like adaptive radiotherapy."
          ]
        },
        {
          audience: "Patients",
          points: [
            "**A Treatment Plan as Unique as You Are:** Receive radiation therapy precisely tailored to your tumor's genetic weaknesses, maximizing its effectiveness.",
            "**Minimize Side Effects:** Benefit from a plan that accounts for your personal genetic makeup to better protect healthy tissues and reduce the risk of long-term complications.",
            "**Therapy That Adapts with You:** Your treatment can be intelligently adjusted over time, responding to changes in your tumor and anatomy for a truly dynamic and personalized approach.",
            "**Empowered Decision-Making:** Receive clear, AI-summarized explanations about your personalized treatment, helping you understand the 'why' behind your care plan."
          ]
        },
        {
          audience: "Researchers & Academia",
          points: [
            "**Generate High-Fidelity Multi-Modal Data:** Create a rich, structured dataset linking genomic predictions, treatment plans, and clinical outcomes to power the next wave of discoveries.",
            "**Accelerate Radio-Genomic Discovery:** Utilize a powerful analytical suite to investigate novel biomarkers, test radiobiological hypotheses, and develop new treatment paradigms.",
            "**Enable Next-Generation Clinical Trials:** Precisely stratify patient cohorts for trials of novel agents and radiation techniques, increasing the likelihood of success."
          ]
        },
        {
          audience: "Healthcare Institutions & Payers",
          points: [
            "**Drive Value-Based Care:** Improve patient outcomes and lower long-term costs by reducing treatment failures and severe toxicities through hyper-personalized therapy.",
            "**Become a Leader in Precision Oncology:** Differentiate your institution as a center of excellence by deploying a cutting-edge AI platform for personalized radiation therapy.",
            "**Optimize Resource Allocation:** Leverage data-driven insights to streamline service delivery, justify resource needs, and demonstrate superior value to payers and patients."
          ]
        }
      ],
      conclusion: "The PrecisionRad Co-Pilot represents the convergence of AI, medical imaging, and deep genomics. By transforming multi-modal data into actionable clinical intelligence, it moves radiation oncology from a standardized practice to a deeply personalized science. Our mission is to empower clinicians with a co-pilot that helps deliver the right dose to the right target at the right time, for every patient, based on their unique molecular and anatomical landscape."
      },
  "agentic-emr": {
    "slug": "agentic-emr",
    "pageTitle": "Oncology Co-Pilot: AI-Powered Cancer Care Coordination",
    "heroSubtitle": "From complex data to decisive action. An AI Co-Pilot for oncologists that integrates deep genomic analysis, clinical trial matching, and collaborative tools to personalize and accelerate cancer treatment.",
    "vision": "To create a future where every oncology care team is augmented by an intelligent AI partner. Our Co-Pilot transforms complex patient data—from genomics to clinical history—into clear, actionable insights, streamlining care coordination, accelerating research, and empowering clinicians to deliver the most advanced and personalized cancer care possible.",
    "coreProblemIntro": "Traditional EMR systems, while essential, are not equipped for the complexities of modern oncology, often contributing to the burden on care teams. Key challenges include:",
    "coreProblemPoints": [
      "Managing overwhelming volumes of complex data: clinical notes, lab trends, pathology, and multi-gene genomic reports.",
      "Rapidly interpreting the clinical significance of genomic variants, including Variants of Unknown Significance (VUS).",
      "The time-intensive process of identifying eligible patients for cutting-edge clinical trials.",
      "Lack of integrated tools to translate genomic findings into research or therapeutic strategies (e.g., CRISPR).",
      "Fragmented communication and coordination across multi-disciplinary teams (oncologists, surgeons, radiologists, pathologists)."
    ],
    "keyCapabilities": [
      {
        "title": "Advanced Genomic Analysis & Interpretation",
        "business": "Empowers clinicians to understand the functional impact of genetic mutations, moving beyond simple presence/absence to predict pathogenicity and treatment response.",
        "technical": "Leverages the `GenomicAnalystAgent` with a simulated advanced VEP model (Evo2-style) to calculate delta likelihood scores and confidence levels for variants, using a `mock_evo2_api` for demonstration.",
        "scientific": "Based on principles of deep learning for variant effect prediction, translating raw genomic data into clinically relevant classifications like 'activating mutation' or 'resistance marker'."
      },
      {
        "title": "Intelligent Clinical Trial Matching & Eligibility Screening",
        "business": "Drastically reduces the manual effort required to find suitable clinical trials for patients, increasing access to novel therapies.",
        "technical": "Utilizes a `ClinicalTrialAgent` and `EligibilityDeepDiveAgent` to perform a multi-stage analysis. First, it uses vector search over a pre-processed trial database (ChromaDB), then an LLM-powered agent performs a deep-dive, criterion-by-criterion eligibility check against a structured patient profile.",
        "scientific": "Applies Natural Language Processing and Information Retrieval techniques to parse complex eligibility criteria and match them against structured and unstructured patient data."
      },
      {
        "title": "Seamless Research-to-Therapy Translation (Evo2-to-CRISPR)",
        "business": "Bridges the gap between genomic discovery and experimental therapeutic design by creating a direct workflow from a high-impact variant to a potential gene-editing strategy.",
        "technical": "The `MutationExplorer` UI allows users to select a variant, view its AI-predicted impact, and with one click, pass its precise genomic coordinates via URL parameters to an integrated 'AI-Powered CRISPR Research Assistant' application.",
        "scientific": "Demonstrates a proof-of-concept for a precision medicine pipeline, connecting in-silico functional genomics with the tools for targeted in-vitro/in-vivo research."
      },
      {
        "title": "Context-Aware Collaboration Hub & Agentic Workflow Automation",
        "business": "Fosters real-time, context-rich collaboration between specialists and automates routine tasks, ensuring the entire care team is aligned and informed.",
        "technical": "Implements a WebSocket-based real-time consultation feature with explicit message lineage tracking. Allows for in-chat agent invocation (e.g., `/summarize`) and features specialized agents like `ComparativeTherapyAgent` and `PatientEducationDraftAgent` to provide decision support directly within the collaborative workflow.",
        "scientific": "Explores human-computer interaction models for collaborative AI, where agents act as active participants in clinical discussions to provide on-demand analysis and information synthesis."
      }
    ],
    "buildsOnStackIntro": "The Oncology Co-Pilot is built on a sophisticated AI agent architecture, where specialized agents collaborate to provide deep, contextual insights. It moves beyond simple data retrieval to perform complex analysis and workflow automation:",
    "buildsOnStackPoints": [
      "**Deep Variant Interpretation with `GenomicAnalystAgent`:** Instead of just listing mutations, the `GenomicAnalystAgent` assesses their functional impact. For a patient with a BRAF V600E mutation, it identifies it as a known 'activating mutation', providing immediate clinical context.",
      "**Automated Eligibility Screening with `EligibilityDeepDiveAgent`:** For a trial requiring 'ECOG performance status of 0 or 1' and 'no prior chemotherapy', the agent automatically scans the patient's record, flags the ECOG score from notes, confirms the absence of prior chemo from the treatment history, and reports a 'MET' status.",
      "**From Analysis to Action with the CRISPR Integration:** The platform identifies a pathogenic TP53 mutation, and the `MutationExplorer` not only shows the AI's impact analysis but also provides a 'Design CRISPR Guides' button, directly linking the research finding to a potential therapeutic design workflow.",
      "**Contextual Decision Support in Consultations:** During a real-time chat about managing a patient's side effects, a clinician can invoke the `ComparativeTherapyAgent` to ask, 'What are alternative treatments with less glucose impact?', receiving an AI-generated summary of options directly in the conversation.",
      "**Proactive Patient Management via Custom Agents:** Using the 'Agent Studio' concept, a clinician can create a custom agent to 'Monitor all my patients with EGFR T790M for new publications on resistance pathways', automating a highly specific and time-consuming research task.",
      "**Holistic Patient Summarization with `DataAnalysisAgent`:** Before a patient visit, the `DataAnalysisAgent` can be triggered to generate a 'deep dive' summary, pulling not just the latest lab values but also insights from conceptual agents like 'Integrative Medicine' or 'Comparative Therapy' to provide a truly holistic patient overview."
    ],
    "genomicUseCasesGrid": [
      { "label": "Deep Variant Interpretation (`GenomicAnalystAgent`)", "iconName": "Beaker", "color": "text-purple-400" },
      { "label": "Automated Trial Eligibility Screening (`EligibilityDeepDiveAgent`)", "iconName": "Users", "color": "text-blue-400" },
      { "label": "From Analysis to Action (Evo2-to-CRISPR)", "iconName": "Layers", "color": "text-green-400" },
      { "label": "Contextual In-Consult AI Agents", "iconName": "Lightbulb", "color": "text-yellow-400" },
      { "label": "Custom Agent-Driven Research Monitoring", "iconName": "Activity", "color": "text-orange-400" },
      { "label": "Holistic Patient Summaries (`DataAnalysisAgent`)", "iconName": "Shield", "color": "text-red-400" }
    ],
    "valuePropositionSections": [
      {
        "audience": "For Oncologists & Care Teams",
        "points": [
            "Dramatically reduce time spent on data analysis and trial searching.",
            "Instant access to interpreted genomic insights and eligibility reports.",
            "Enhanced clinical decision-making with AI-driven variant interpretation and therapy suggestions.",
            "Reduced cognitive load and burnout.",
            "More face-to-face time with patients."
        ]
      },
      {
        "audience": "For Oncology Departments & Research Institutions",
        "points": [
            "Accelerated research-to-treatment cycles.",
            "Increased patient enrollment in high-value clinical trials.",
            "Streamlined care coordination across multi-disciplinary teams.",
            "Enhanced data quality for reporting and analytics.",
            "Attraction and retention of top clinical and research talent."
        ]
      },
      {
        "audience": "For Patients",
        "points": [
            "More engaged and focused clinicians.",
            "Faster access to personalized treatment options and clinical trials.",
            "Improved care coordination and safety.",
            "Clearer understanding of their care plan through AI-assisted communication tools."
        ]
      }
    ],
    "conclusion": "The Oncology Co-Pilot is more than an assistant; it's an active member of the cancer care team. By translating vast and complex genomic and clinical data into clear, actionable intelligence, it empowers clinicians to make faster, more informed decisions. It bridges the critical gap between cutting-edge research and personalized patient care, accelerating the promise of precision oncology for every patient."
  },
  "crispr-intelligence": {
    slug: "crispr-intelligence",
    pageTitle: "CRISPR Intelligence: AI-Powered Therapeutic Intelligence Platform",
    heroSubtitle: "Accelerating the discovery and development of CRISPR-based therapies with advanced AI-driven insights and in-silico experimentation.",
    vision: "To democratize and accelerate the design of safe and effective CRISPR-based therapeutics by providing a comprehensive, AI-powered platform. CRISPR TI empowers researchers to rapidly identify novel therapeutic targets, design optimal gRNAs, predict and mitigate off-target effects, and streamline experimental workflows, ultimately bringing life-changing gene therapies to patients faster.",
    coreProblemIntro: "Developing CRISPR-based therapies is complex, facing challenges in target validation, guide RNA efficacy, and safety. Key bottlenecks include:",
    coreProblemPoints: [
      "Complex & Iterative gRNA Design: Designing optimal guide RNAs (gRNAs) with high on-target efficiency and minimal off-target effects is a multi-factorial challenge requiring sophisticated prediction tools and careful consideration of genomic context.",
      "Data Overload & Outcome Interpretation: Analyzing results from CRISPR experiments (e.g., via CRISPResso2) generates complex data that can be difficult to interpret in terms of editing efficiency, allele complexity, and functional consequences, especially in relation to therapeutic goals.",
      "Experiment Planning Inefficiencies: Designing effective validation experiments, choosing appropriate vectors, controls, and analytical methods can be time-consuming and requires deep expertise.",
      "Lack of Integrated Therapeutic Context: Researchers often struggle to connect *in silico* designs and *in vitro/ex vivo* results with the broader challenges of therapeutic development, such as delivery, immunogenicity, durability, and clinical efficacy.",
      "Fragmented Tools & Workflows: Scientists often rely on a disparate set of tools for different stages of the CRISPR workflow, leading to inefficiencies and potential loss of context.",
      "Steep Learning Curve: The rapidly evolving landscape of CRISPR technologies and associated bioinformatics can be daunting for researchers."
    ],
    genomicInsightsOverview: "The CrisPRO platform's core AI-driven `analyze_single_variant` capability provides deep genomic insights applicable across many CRISPR R&D facets, including its role in interpreting VUS, assessing on-target variations, predicting edit consequences, refining target selection, validating disease models, and stratifying experiments. This foundational analysis ensures more informed decisions throughout the CRISPR workflow.",
    keyCapabilities: [
 // This is a conceptual representation. You'll integrate these into your actual data structure.
  {
    title: "Intelligent Guide RNA Design & Optimization (CHOPCHOP Enhanced)",
    technical: "CrisPRO's intelligent design module uses advanced algorithms like DeepHF for superior on-target efficiency prediction and provides comprehensive off-target site scoring across the genome. It fully supports an updated library of nuclease options, including Cas9, Cas12, Base, and Prime Editors, each with their specific PAM requirements. An integrated LLM explains the rationale behind top guide RNA (gRNA) candidates and clarifies potential off-target risks.",
    scientific: "This capability enables the rapid and reliable selection of highly potent and specific gRNAs, which is the cornerstone of any successful CRISPR experiment. By computationally minimizing the risk of unwanted genomic alterations from the start, it facilitates the confident design of diverse CRISPR modalities, including gene knockout, homology-directed repair (HDR), base/prime editing, and CRISPRa/i for transcriptional control.",
    business: "Significantly accelerate the initial, critical design phase of your CRISPR R&D pipeline. By reducing wasted resources on suboptimal or unsafe gRNAs and increasing the probability of successful editing outcomes, this feature provides a direct path to faster, more efficient, and more cost-effective therapeutic development.",
    genomicUseCasesParagraph: "Our `analyze_single_variant` AI is integral to intelligent gRNA design by: \n1. **Assessing Target Site Integrity:** Before finalizing a gRNA, the AI analyzes the target genomic region for any known functional variants (SNPs) that could impact gRNA binding efficiency or PAM recognition, preventing failed edits due to patient or cell-line specific genetics. \n2. **Evaluating Potential Off-Target Impact:** For top off-target site predictions, the AI assesses if an unintended edit would fall on a known functionally important variant elsewhere in the genome, allowing for a more sophisticated risk assessment beyond simple sequence similarity. \n3. **Informing gRNA Selection Near Functional Elements:** The AI helps researchers understand if a potential gRNA target site overlaps with or is adjacent to known regulatory elements whose disruption by Cas9 cleavage could have unintended functional consequences."
  },
  {
    title: "Advanced Variant Effect Prediction & Target Contextualization (Evo 2 Integration)",
    technical: "CrisPRO integrates an advanced AI engine, similar to Evo 2 (`analyze_single_variant` API), to deliver deep insights into genetic variations. This system predicts the functional impact of SNVs and indels (providing delta_scores and confidence levels) within or near your gene target. An LLM then contextualizes these AI-driven predictions, explaining their relevance to gene function, disease association, and potential implications for your CRISPR strategy and experimental goals.",
    scientific: "This core capability is critical for robust target validation, allowing researchers to assess if a gene target harbors functional variants that might affect therapeutic efficacy. It provides a clear understanding of the baseline genetic context in disease models or patient-derived cells and is crucial for interpreting the consequences of both intended and unintended edits, or the effects of pre-existing polymorphisms at the target locus.",
    business: "By providing a thorough understanding of the target gene's genetic landscape, this feature significantly de-risks therapeutic programs. It delivers critical data to inform early-stage R&D go/no-go decisions, optimizes target selection, and ultimately increases the probability of downstream success for gene editing therapeutics, saving time and resources.",
    genomicUseCasesParagraph: "The CrisPRO platform's core AI-driven `analyze_single_variant` capability provides deep genomic insights for CRISPR R&D. It enables: \n1. **Interpretation of Variants of Uncertain Significance** (VUS) in target genes to inform therapeutic strategy. \n2. **Assessment of pre-existing genetic variations** within target sequences to predict their impact on editing. \n3. **Prediction of functional consequences** for intended edits (e.g., HDR) or baseline gene function for knockouts. \n4. **Optimization of gRNA target site** selection by avoiding problematic natural variations. \n5. **Validation of genetically defined disease models** by ensuring CRISPR-introduced mutations mimic pathogenic states. \n6. **Stratification of experimental systems** to explain variability based on functional variant impacts. \nThis ensures more informed target selection, robust experimental design, accurate interpretation, and reliable disease modeling."
  },
  {
    title: "Comprehensive Editing Outcome Analysis (CRISPResso2 Enhanced)",
    technical: "CrisPRO's enhanced CRISPResso2 pipeline, supercharged with AI, provides robust, automated parsing and in-depth analysis of your next-generation sequencing (NGS) data from CRISPR experiments. It precisely quantifies NHEJ/HDR efficiencies, characterizes diverse indel mutation patterns, assesses allelic heterogeneity, and identifies potential off-target editing events. An integrated LLM then delivers clear, actionable interpretations of these complex results, directly relating them to your experimental goals and therapeutic implications (e.g., % NHEJ for knockout efficacy).",
    scientific: "This AI-powered analysis delivers precise quantification of all editing outcomes, enabling detailed characterization of DNA repair pathway choices and mutational signatures. It helps identify and quantify unintended events like large deletions or translocations, which are critical for safety assessment. The platform facilitates rigorous comparison of different gRNAs, delivery methods, or experimental conditions, leading to data-driven optimization of editing strategies.",
    business: "Achieve faster, more reliable, and significantly more insightful analysis of your CRISPR experimental results. This provides clearer, more robust data for critical milestone reporting, internal decision-making in therapeutic development, and regulatory submissions. Ultimately, it reduces ambiguity in interpreting complex gene editing profiles, saving time and preventing costly misinterpretations.",
    genomicUseCasesParagraph: "The `analyze_single_variant` genomic engine enhances CRISPR outcome analysis by: \n1. **Assessing Functional Impact of Edits:** It evaluates the predicted biological consequence (e.g., pathogenicity, delta_score) of precise SNVs or small indels that occur as on-target or off-target edits, adding a layer of functional meaning beyond simple quantification. \n2. **Interpreting Allelic Heterogeneity:** When multiple distinct edited alleles are present, `analyze_single_variant` can predict the functional consequence of each, clarifying the overall biological outcome of the experiment. \n3. **Contextualizing Results:** The AI can assess if known background genetic variations in the cell line might have influenced the observed editing efficiency or repair pathway choice, aiding in a more nuanced interpretation of the results."
  },
  {
    title: "LLM-Powered Experiment Design & Protocol Generation (Experiment Advisor)",
    technical: "CrisPRO's Experiment Advisor features interactive LLM agents that act as intelligent partners in your CRISPR experimental design process. Based on your specific gene target, desired edit (knockout, repair, base change), and therapeutic goals, the AI provides dynamic, context-aware recommendations for optimal cell types, nuclease formats (e.g., Cas9, Cas12, BE, PE), delivery methods (viral vectors, RNPs), and downstream analytical strategies. It can also assist in generating customizable experimental protocols.",
    scientific: "This capability promotes the adoption of best practices in CRISPR experimental design by guiding researchers through critical variables and considerations. The AI provides scientifically sound advice tailored to the specific application, such as appropriate vector choice for achieving high HDR rates versus efficient NHEJ, selection of relevant positive and negative controls for therapeutic validation projects, and determining appropriate NGS sequencing depth for accurate outcome assessment.",
    business: "Significantly reduce experimental setup time and overall resource expenditure by optimizing designs from the outset. Improve the success rate, reproducibility, and reliability of CRISPR experiments through AI-guided best practices. This accelerates the learning curve for researchers, particularly those new to specific advanced CRISPR applications or complex experimental setups, boosting overall team productivity.",
    genomicUseCasesParagraph: "The `analyze_single_variant` engine is integral to the Experiment Advisor for CRISPR by: \n1. **Validating Therapeutic Premise:** If correcting a pathogenic variant, the AI first confirms its likely functional impact (pathogenicity, delta_score) to ensure the entire experimental premise is sound before you begin. \n2. **Guiding Disease Model Creation:** If engineering a new disease model, the AI predicts if your intended variant will produce the desired functional consequence (e.g., pathogenic loss-of-function), ensuring you build a valid model. \n3. **Prioritizing gRNA Safety:** During design, the AI can prospectively assess the potential functional impact of edits at predicted off-target sites, allowing you to select the gRNA with the safest profile to move forward with."
  },
  {
    title: "Therapeutic Contextualization & Advanced Insights",
    technical: "The platform integrates specialized LLM prompts and an evolving knowledge base to explicitly link your CRISPR design choices and experimental outcomes to key downstream therapeutic development challenges. This includes considerations for efficacy, optimal delivery strategies, comprehensive off-target safety validation approaches (e.g., GUIDE-seq, CIRCLE-seq recommendations), potential immunogenicity of the Cas protein or gRNA, durability of the intended edit, and possible side effects. It also features integration with automated literature analysis tools for the latest context.",
    scientific: "This crucial capability encourages researchers to adopt a translational mindset from the earliest stages of R&D. It proactively highlights potential downstream hurdles and opportunities for therapeutic candidates, providing a structured framework for assessing the overall clinical and commercial viability of a specific CRISPR-based therapeutic strategy. It helps bridge the gap between bench-level discoveries and the complex path to clinical application.",
    business: "Enable early identification of potential risks, bottlenecks, and critical success factors within a therapeutic development program. This allows for better alignment of R&D efforts and resource allocation with key clinical and commercial endpoints, significantly improving the probability of successful translation from lab to clinic and maximizing the potential return on investment.",
    genomicUseCasesParagraph: "`analyze_single_variant` provides critical data for therapeutic contextualization by: \n1. **Defining Therapeutic Efficacy:** For gene correction, the AI confirms that a starting pathogenic variant was successfully converted to a predicted benign one, providing a functional measure of success. \n2. **Quantifying True Off-Target Risk:** It moves beyond simple detection rates by predicting the biological risk (e.g., pathogenicity, delta_score) of any experimentally verified off-target edits, providing a crucial safety metric for therapeutic candidates. \n3. **Assessing On-Target Functional Outcomes:** The AI's prediction of how specific on-target edits alter protein function (even if not a simple reversion) is vital for assessing overall therapeutic potential and anticipating biological effects."
  }
  ],
    buildsOnStackIntro: "The foundational `analyze_single_variant` capability (Evo 2-style), providing functional impact predictions, confidence scores, and delta_scores for mutations, is pivotal for the CrisPRO platform. It enables these core genomic use cases:",
    buildsOnStackPoints: [
      "**Perform VUS Interpretation (Target/Disease Context):** If the CRISPR target gene is implicated in a hereditary disease, the AI assesses the impact of known Variants of Uncertain Significance (VUS), providing crucial context for therapeutic rationale or characterization of patient-derived cell lines.",
      "**Predict Functional Impact of On-Target Genetic Variation:** Before designing gRNAs, the AI assesses if pre-existing variants within the target gene sequence (especially in patient-derived samples) might alter its function or response to editing, ensuring robust therapeutic design.",
      "**Assess Potential Functional Consequences of Intended Edits:** For precise editing (HDR, base/prime editing), the AI predicts the functional impact of the desired allelic change. For NHEJ-knockout, it helps understand the functional baseline of the gene being disrupted.",
      "**Refine Target Site Selection for gRNAs:** The AI helps avoid targeting regions where natural genetic variation might complicate experimental interpretation or where off-target effects on functionally important nearby variants could occur.",
      "**Guide Development of Genomically Defined Disease Models:** When creating cellular or animal models of disease using CRISPR, the AI's variant effect prediction ensures the introduced mutations accurately reflect pathogenic states, improving model validity.",
      "**Stratify Experimental Systems & Explain Variability:** The AI can help group cell lines or experimental cohorts based on the predicted functional impact of variants in the target gene or related pathways, potentially explaining observed variability in CRISPR editing outcomes or downstream phenotypes."
    ],
    genomicUseCasesGrid: [
      { label: "Perform VUS Interpretation (Target/Disease Context)", iconName: "Lightbulb", color: "text-yellow-400" },
      { label: "Predicting On-Target Efficacy & Specificity", iconName: "Activity", color: "text-blue-400" },
      { label: "Forecasting Off-Target Editing Risks", iconName: "Shield", color: "text-red-400" },
      { label: "Optimizing gRNA Design & Delivery", iconName: "Layers", color: "text-green-400" },
      { label: "Guiding HDR Strategies & Donor Design", iconName: "Beaker", color: "text-purple-400" },
      { label: "Stratifying Studies & Biomarker ID", iconName: "Users", color: "text-orange-400" }
    ],
    valuePropositionSections: [
  {
    audience: "For Scientists & Research Labs",
    points: [
      "Design with Unprecedented Confidence: Leverage best-in-class AI to design highly potent and specific guide RNAs from the start, dramatically increasing the success rate of your editing experiments and minimizing costly validation cycles.",
      "Go from Raw Data to Actionable Insight, Faster: Let our AI Co-Pilot handle the heavy lifting of complex NGS data analysis and therapeutic contextualization, transforming your experimental results into clear, decision-ready insights in a fraction of the time.",
      "Democratize Advanced Computational Biology: Access a suite of sophisticated AI tools for variant effect prediction, off-target analysis, and experimental design, without needing a dedicated bioinformatics team. Focus on your science, not on building analysis pipelines.",
      "Produce High-Impact, Publishable Results: Generate higher quality, more reproducible data with AI-guided experimental design and analysis, strengthening your publications, grant applications, and contributions to the field."
    ]
  },
  {
    audience: "For Biotechnology & Pharmaceutical Leaders",
    points: [
      "De-Risk Your Therapeutic Pipeline: Make more informed go/no-go decisions with AI-driven insights into target validity, off-target safety, and potential translational hurdles, significantly reducing the risk profile of your preclinical programs.",
      "Accelerate Timelines to the Clinic: Shorten the entire discovery and preclinical development cycle for CRISPR therapies by streamlining design, automating complex analysis, and contextualizing results for therapeutic viability from day one.",
      "Build a Moat Around Your IP: Strengthen your intellectual property position with novel, highly optimized, and well-characterized gene editing strategies and therapeutic candidates designed and validated through the platform.",
      "Maximize Your R&D Investment: Improve the overall efficiency and success rate of your therapeutic programs, ensuring your resources are focused on the most promising candidates and strategies, leading to a higher potential return on investment."
    ]
  }
],
    conclusion: "CrisPRO was created to bridge the critical gap between the immense promise of CRISPR and the complex reality of therapeutic development. It is an end-to-end intelligence partner that replaces fragmented workflows with a unified, AI-guided journey. From designing the most precise gRNA to interpreting the most complex editing outcomes and contextualizing them for therapeutic viability, CrisPRO is the integrated platform designed to deliver on the ultimate goal: turning groundbreaking science into life-changing genetic medicines."      
  }
}; 